International Journal of Banking, Risk and Insurance

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Investment Risk Identification and its Assessment:A Study of Indian Pharmaceutical Sector


Affiliations
1 NMIMS, Bangalore, India
2 Thomson Reuter, India
     

   Subscribe/Renew Journal


The pharmaceutical industry is undergoing rapid transformation, as the pharmacy companies are facing pressure from governments and public for reduction in prices of life-saving drugs and initiating outcome-based pricing. India's pharmaceutical industry has been growing at record levels from past ten years. Even though the sector has a very huge potential to grow, from last couple of years it is facing major loss as there is a dip in investments due to sector specific risks as legal, safety, market to name a few. This industry's deep-ischolar_mained position as a global leader in the production of high-quality generic medicines is set to harvest significant new benefits as the patents on a number of blockbuster's drugs are about to expire over the next few years. Safety, policy, regulatory, contingency planning, various investment risks identified in this paper which are involved in the pharmaceutical, lead to fall in investments. The severity impact of all above identified investment risks on investment is analysed using factor analysis. Most influential risks are enumerated and simultaneously presented using graphical method as tornado chart.

Keywords

Pharmacy Sector, Risk Identification, Impact Assessment, Risk Mitigation.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Abzakh, A. A., Ling, K. C., & Alkilani, K. (2013). The impact of perceived risks on the consumer resistance towards generic drugs in the Malaysia pharmaceutical industry. International Journal of Business and Management, 8(3), 42-51. http://doi.org/10.5539/ijbm.v8n3p42

  • Alkhateeb, F. M., Clauson, K. A., Khanfar, N. M., & Latif, D. A. (2008). Legal and regulatory risk associated with Web 2.0 adoption by pharmaceutical companies. Journal of Medical Marketing, 8(4), 311-318. Retrieved from http://doi.org/10.1057/jmm.2008.20

  • Anderson, T., Pharmaceuticals, G., Scannell, J., Ph, D., Devices, E. H., Pharma, M., … Bernstein, S. (1994). European Pharmaceuticals and Healthcare: Investment Controversies and Recommendations, 75-95.

  • Cabral, W., Junior, D. S., & Reid, J. (2010). Uncertainties in Amazon Hydropower Development : Risk Scenarios and Environmental Issues around the Belo Monte Dam. Amazon Hydropower Development, 3(2), 249-268.

  • Castaldi, D., Chastain, E., Windram, M., Ziatyk, L., & Sciences, M. (2003). A Study of Hydroelectric Power: From a Global Perspective to a Local Application.

  • Edwards, B., & Chakraborty, S. (2012). Risk Communication and the Pharmaceutical Industry. Drug Safety. http://doi.org/10.2165/11635220-000000000-00000

  • Grabowski, H., & Vernon, J. (1990). A new look at the retuns and risks to pharmaceutical R&D. Management Science, 36(7), 804-821. Retrieved from http://doi.org/10.1287/mnsc.36.7.804

  • Karatzas, I., & Shreve, S. (1991). Brownian motion and stochastic calculus. Berlin/New York/London: SpringerVerlag.

  • Morgan, G., Apt, J., & Lave, L. (2005). Electric power sector and climate change mitigation. Pew Center: Global Climate Change.

  • Moran, N. (2012). BIO 2012: Implications of the ‘Patent Cliff’. BioWorld Today.

  • Kalantzopoulos, N. A., Hatzigeorgiou, A. M., & Spyridis, T. C. (2008). Modeling uncertainty and risk in investment appraisal decisions: A monte carlo simulation, 58(3), 167-183.

  • Mittal, G. (2004). Real options approach to capacity planning under uncertainty.

  • Prentis, R. A., Walker, S. R., Heard, D. D., Tucker, A. M., & Wiley, J. (2009). Innovation Pharmaceutical UK Investment in the R&D, 9(3), 197-203.

  • Palnitkar, U. (2013). The Indian pharmaceutical industry. Ernst and Young-pharma focus Asia.

  • Reepmeyer, G., Gassmann, O., & Ruther, F. (2011). Out-licensing in markets with asymmetric information: The case of the pharmaceutical industry. International Journal of Innovation Management, 15(4), 755-795. Retrieved from http://doi.org/10.1142/S1363919611003313

  • Roy, N. C. (2012). Risk assessment and distribution in small hydro power projects : A fuzzy. AIMS International, 7(2).

  • Shafiei, N., Ford, J. L., Morecroft, C. W., & Lisboa, P. J. (2013). Transformation in the Pharmaceutical Industry: Transformation-Induced Quality Risks - A Survey Transformation in the Pharmaceutical Industry : Transformation-Induced Quality Risks A Survey. Retrieved from http://doi.org/10.5731/pdajpst.2013.00917

  • Scholleova, H., Fotr, J., & Svecova, L. (2010). Investment decision making criterions in practice. Economics and Management, 2010(15), 1018-1023.

  • Sharma, K., & C. K. (2013). Uncertainty principle-Disgraced Ranbaxy.

  • Simchi-Levi, D. (2010). How to mitigate risk based on business objectives.

  • Singh, K. (2013). New Pharma Pricing Policy.

  • Spiker.B. (2003). Reducing pharmaceutical risk.

  • Yang, A. (2013). Decision making for individual investors: A measurement of latent difficulties.


Abstract Views: 221

PDF Views: 3




  • Investment Risk Identification and its Assessment:A Study of Indian Pharmaceutical Sector

Abstract Views: 221  |  PDF Views: 3

Authors

Neha Chhabra Roy
NMIMS, Bangalore, India
Basava Rajesh Beera
Thomson Reuter, India

Abstract


The pharmaceutical industry is undergoing rapid transformation, as the pharmacy companies are facing pressure from governments and public for reduction in prices of life-saving drugs and initiating outcome-based pricing. India's pharmaceutical industry has been growing at record levels from past ten years. Even though the sector has a very huge potential to grow, from last couple of years it is facing major loss as there is a dip in investments due to sector specific risks as legal, safety, market to name a few. This industry's deep-ischolar_mained position as a global leader in the production of high-quality generic medicines is set to harvest significant new benefits as the patents on a number of blockbuster's drugs are about to expire over the next few years. Safety, policy, regulatory, contingency planning, various investment risks identified in this paper which are involved in the pharmaceutical, lead to fall in investments. The severity impact of all above identified investment risks on investment is analysed using factor analysis. Most influential risks are enumerated and simultaneously presented using graphical method as tornado chart.

Keywords


Pharmacy Sector, Risk Identification, Impact Assessment, Risk Mitigation.

References